Enzymatica AB is an organization based in Lund that specializes in barrier technology aimed at providing protection against common colds. The company has developed ColdZyme®, a product designed to reduce the duration and symptoms of colds. Enzymatica AB supports its claims with independent study results, which are available for review, highlighting the efficacy of their innovative research on ColdZyme®.
In addition to its product offerings, Enzymatica AB provides various resources for stakeholders, including press releases that keep the public informed about company updates and developments. Financial reports are accessible, allowing for transparency regarding the organization's financial health. The company also maintains a financial calendar to assist in planning and offers articles and insights on health topics, contributing to the broader discourse on health and wellness.